viewAntibe Therapeutics Inc

Antibe Therapeutic's Phase 2B trial safety results for pain drug ATB-346 published in British Journal of Pharmacology

A new research article in the British Journal of Pharmacology highlights the success of Antibe's 2B GI safety trial for its lead pain treatment ATB-346

Toronto-based Antibe develops safer, non-addictive medicines for pain and inflammation

Antibe Therapeutics Inc (CVE:ATE), a commercial-stage healthcare company, alerted investors Tuesday about a new research article in the British Journal of Pharmacology regarding the successful 2B GI safety trial for its lead drug ATB-346.

ATB-346 is a hydrogen sulfide-releasing derivative of naproxen, a non-steroid anti-inflammatory drug that is used to relieve pain from various conditions.

READ: British Journal of Pharmacology research article

Non-steroidal anti-inflammatory drugs such as naproxen are common pain therapies for osteoarthritis and gout, but their use is associated with a high incidence of gastrointestinal ulceration and bleeding.

The results of the safety study published in the British Journal of Pharmacology provide evidence that ATB-346 is less toxic, but as effective as naproxen in alleviating pain, according to John Wallace, Antibe’s chief scientific officer.

“We are pleased that the results of our Phase 2B GI safety study for ATB-346 have been published in BJP,” Wallace said in a statement. “The results provide unequivocal evidence for a dramatic reduction of GI toxicity of ATB‐346 as compared to naproxen, with equivalent suppression of the enzyme (cyclooxygenase; COX) that produces substances that cause pain.”

Headquartered in Toronto, Antibe develops non-addictive medicines for pain and inflammation.

Contact Ellen Kelleher at ellen@proactiveinvestors.com

Quick facts: Antibe Therapeutics Inc

Price: 5.12 CAD

Market: TSX
Market Cap: $233 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company...


Antibe Therapeutics releases data from company’s Phase II placebo-controlled...

Antibe Therapeutics (CVE: ATE) CEO Dan Legault joined Steve Darling from Proactive Vancouver with new results from the company’s analysis of primary and secondary data from ATB-346’s recent placebo-controlled efficacy trial. Legault shares the data with Proactive and he also maps out the...

on 08/12/2020

2 min read